Mclean Hospital
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Mclean Hospital sits in the top decile of US sponsors by registered trial count (#201 of 15,742 sponsors by registered trial count).
Mclean Hospital: 140 sponsored US clinical trials, 26 recruiting.
Mclean Hospital sponsors 140 registered US clinical trials on ClinicalTrials.gov, 26 of them currently recruiting, and 92 completed. 13 of these trials are in Phase 3-4 (later-stage) and 40 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Major Depressive Disorder, with 9 trials.
Top-decile sponsor footprint
Mclean Hospital ranks in the top decile of sponsors by registered trial count (#201 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
92 of 110 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
140 total, page 2 of 3
Feasibility of Collateral Information Review and Its Impact on Clinical Decision-Making
NCT04635748
Electrophysiological Correlates of Cognition in Depression
NCT03998748
Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders
NCT03943537
Stress Response in Opioid Use Disorder
NCT03616379
Cognitive Bias Modification for OCD
NCT03799419
Augmenting Hospitalization for Serious Mental Illness: Cognitive Bias Modification
NCT03509181
Electronic Media and Its Application in Psychotherapy
NCT03712267
Cognitive Control Training for Urgency in a Naturalistic Clinical Setting
NCT03527550
Alkontrol-herbal Effects on Alcohol Drinking
NCT03099590
Sex, Hormones and Gamma-Aminobutyric Acid (GABA) in Stress Induced Anhedonia in Depression
NCT03031665
The Effects of Nicotinamide Riboside Supplementation on Brain NAD+/NADH Ratio and Bioenergetics
NCT03151707
McLean and Genomind Prospective Study
NCT03113890
Brain Neurochemical Profile During Marijuana Abstinence
NCT04320537
Hippocampal Plasticity of Young Adults With Childhood Adversity
NCT02816502
Effects of Litebook EDGE™ Phototherapy on Academic Performance and Brain Activity
NCT05383690
Riluzole Effects on Hippocampus Biomarkers
NCT04630444
LFMS: Initial Trial in Geriatric Bipolar Depression
NCT02707276
Neuroimaging Studies of Reward Processing in Depression
NCT03026036
Cannabidiol Pharmacotherapy for Adults With Cannabis Use Disorder
NCT03102918
Targeting Cerebellum to Treat Psychosis: a Transcranial Magnetic Stimulation (TMS) Study
NCT02642029
Examining Reward-Related Predictors and Mechanisms of Change in BA Treatment for Anhedonic Adolescents
NCT02498925
Effect of Nicotine on Brain Reward Pathways
NCT02346539
Fixed Dose Intervention Trial of New England Enhancing Survival in SMI Patients
NCT02188121
Study of Treatment for Opioid Dependence and Anxiety Disorders
NCT02252068
Building an Outcomes Assessment Infrastructure to Assess Anxiety Treatment
NCT02305537
A Trial of Intranasal Ketamine for the Treatment of Obsessive-Compulsive Disorder
NCT02234011
Brain Mechanisms of Human Motivation
NCT01976975
An Investigation of Early Life Stress and Depression
NCT01701258
Neural Mechanisms Underlying Nicotine and Alcohol Combinations
NCT02049268
Psychoeducation of Borderline Patients
NCT01719731
Multiple Treatment Study Using Low Field Magnetic Stimulation for Bipolar Depression
NCT01929681
Spectroscopic Imaging at 4T: A Drug Challenge Study
NCT01577706
Genetic and Neural Predictors of Adolescent Depression
NCT01743716
Predicting Cognitive Resilience Against Sleep Loss
NCT01651429
D-cycloserine (DCS) Pretreatment + CBT + Nicotine Replacement Therapy for Smoking Cessation (DCS)
NCT01842334
Brain Mechanisms of Emotion and Motivation: A Mind-Body Study
NCT01850472
Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders
NCT01720316
Longitudinal Multimodal Neuroimaging Studies in Patients With First Episode Psychosis
NCT01688765
Neural Components Underlying the Treatment of Adolescent Depression
NCT01717508
Internet Based Cognitive Behavioral Therapy Effects on Depressive Cognitions and Brain Function
NCT01598922
Assessing Models of Exposure Therapy
NCT01679457
Functional and Neurochemical Correlates of Treatment Response in Major Depressive Disorder
NCT01598324
Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia
NCT01598896
Glutamatergic and GABAergic Mediators of Antidepressant Response in Major Depression
NCT01557946
Simultaneous FMRI and NIRS to Estimate Brain Cerebral Metabolism
NCT01825096
The Effects of Dopamine on Reward Processing
NCT01253421
Depression and Dopamine Transporter Function Study Using C-11 Altropane
NCT01701141
Exploring the Effects of Coenzyme Q10 on Bioenergetics Metabolism in Geriatric Bipolar Depression
NCT01390389
Treatment to Enhance Cognition in Bipolar Disorder
NCT01470781
Dopamine Neurotransmission in Major Depression
NCT01659814
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 19 |
| Phase 2 | 21 |
| Phase 3 | 3 |
| Phase 4 | 10 |
Therapeutic Areas
What is open in the Mclean Hospital pipeline
26 recruiting of 140 indexed (19% open); 92 completed (66%).
Phase mix: 13 late (III/IV) vs 40 early (I/II) (early-phase heavy).
Top condition: Major Depressive Disorder (9 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Mclean Hospital: open-pipeline peers nationwide
Peers matched on 140 registered trials and 19% open enrollment, not the therapeutic-area sidebar.
Mclean Hospital sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 140 trials (± recruiting share)
- Case Western Reserve University · 141 trials · 16% recruiting
- Eastern Cooperative Oncology Group · 141 trials · 3% recruiting
- Purdue University · 141 trials · 10% recruiting
- Barbara Ann Karmanos Cancer Institute · 139 trials · 12% recruiting
Sponsors near 19% open enrollment (± trial volume)
- Children's Hospital Medical Center, Cincinnati · 19% recruiting · 571 trials
- Arkansas Children's Hospital Research Institute · 19% recruiting · 97 trials
- University of Missouri-Columbia · 19% recruiting · 291 trials
- Montefiore Medical Center · 19% recruiting · 345 trials
Related
What to do with this Mclean Hospital page
140 registered trials is a research-attention snapshot, not an endorsement of Mclean Hospital or any single study.
- 26 of Mclean Hospital's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Major Depressive Disorder is the condition Mclean Hospital studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Major Depressive Disorder trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Mclean Hospital pipeline card: 140 registered trials from official public datasets.Report a data error.